OVXA Stock Overview
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ovoca Bio plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.006 |
| 52 Week High | €0.13 |
| 52 Week Low | €0.005 |
| Beta | 0.68 |
| 1 Month Change | 20.00% |
| 3 Month Change | -40.00% |
| 1 Year Change | n/a |
| 3 Year Change | -96.00% |
| 5 Year Change | -90.00% |
| Change since IPO | -98.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| OVXA | IE Pharmaceuticals | IE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 1.5% |
| 1Y | n/a | 7.5% | 15.4% |
Price Volatility
| OVXA volatility | |
|---|---|
| OVXA Average Weekly Movement | 24.2% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in IE Market | 5.7% |
| 10% least volatile stocks in IE Market | 2.8% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 5 | Kirill Golovanov | ovocabio.com |
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018.
Ovoca Bio plc Fundamentals Summary
| OVXA fundamental statistics | |
|---|---|
| Market cap | €489.38k |
| Earnings (TTM) | -€2.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs OVXA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OVXA income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €2.33m |
| Earnings | -€2.33m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OVXA perform over the long term?
See historical performance and comparison